Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Objective To explore the efficacy and safety of icotinib with chemotherapy as first-line therapy for advanced lung adenocarcinoma in patients with sensitive epidermal growth factor receptor (EGFR) mutations. Methods This prospective, randomized, cont
Autor:
Howard A. Burris, F. Anthony Greco, Davey B. Daniel, John D. Hainsworth, David R. Spigel, Tarek Mekhail, John D. Zubkus, Dianna Shipley, David M. Waterhouse
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 117
Purpose First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. Amrubicin is a synthetic anthracycline with single-agent activity in relapsed/refractory SCL
Autor:
Hans Werner Tessen, TLK-Group, Norbert Marschner, Roland Schnell, Jochen Eggert, L. Spring, Ulla von Verschuer, Martina Jänicke, Adrian Binninger
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 112
Objectives Real-life data on advanced non-small cell lung cancer (NSCLC) are centrally important to complement the results from clinical trials and to improve the standard of care. We present data on the choice of systemic first- and second-line trea
Autor:
Kent C. Shih, David M. Waterhouse, Howard A. Burris, Victor M. Priego, John D. Hainsworth, Michael McCleod, David R. Spigel, Ralph V. Boccia, Reed Brian Mitchell, F. Anthony Greco, Fred J. Kudrik
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 118
Objectives The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC. In this pilot phase II trial, we evaluated the feasibility of using pemetrexed and carboplatin as neoadjuvant therapy, prior
Autor:
Masamoto Nakanishi, Katsuyuki Kiura, Daijiro Harada, Toshio Kubo, Shoichi Kuyama, Toshiaki Okada, Daizo Kishino, Kadoaki Ohashi, Nobuaki Ochi, Tomoko Yamagishi, Takahiro Umeno, Genyo Ikeda, Eiki Ichihara, Mitsune Tanimoto, Kenichi Chikamori, Nobukazu Fujimoto, Nagio Takigawa, Akihiro Bessho, Katsuyuki Hotta
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 112
Introduction S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium. Although the combination of S-1 with carboplatin is a first-line chemotherapy regimen for advanced non-small cell lung cancer (NSCLC), the e
Autor:
Koichi Hagiwara, Ichiro Kinoshita, Yoshihito Ohhara, Makoto Maemondo, Hiroshi Kagamu, Hiroshi Watanabe, Atsuto Mouri, Shunichi Sugawara, Masaru Nishitsuji, Hiroshi Sakai, Akira Inoue, Yuka Fujita, Kunihiko Kobayashi, Kazuhiro Usui
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 99
Vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of malignant pleural effusion (MPE). Here, a multicenter phase II trial to evaluate bevacizumab in non-squamous non-small cell lung carcinoma patients with MPE was con
Autor:
Ki Hoon Park, Seung Joon Kim, Kyo Young Lee, Eun-Jung Lee, Chan Kwon Park, Hyung Kyu Yoon, Youn Soo Lee, Chang Dong Yeo, Sang Haak Lee, Tae-Jung Kim
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 87(3)
Objectives Expression of insulin-like growth factor 1 receptor (IGF-1R) in non-small cell lung cancer (NSCLC) is associated with poor prognosis. The IGF-1R pathway activates downstream targets that bypass dependency in signals from the epidermal grow
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 85(2)
Objectives The role of estrogen signaling in lung cancer remains unresolved. We investigate the influence of serum estrogenic compounds and estrogen receptor (ERα and ERβ) mediated bioactivity on lung cancer outcomes. Materials and methods Serum sa
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 82(3)
Background Malignant mesothelioma (MM), a primarily asbestos-induced tumour, has a poor prognosis, with over-all 5-year survival less than 5%. Tumour biomarkers are being intensely investigated in MM as aids to diagnosis and prognosis. Hyaluronic aci
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 73(3)
We investigated the clinical significance of Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) during angiogenesis in non-small-cell lu